問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

Recruiting

List

769Cases

2026-03-01 - 2043-12-31

Phase III

Active
A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Adjuvant Placebo Plus MK-3475A in Participants With Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer Following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    錠劑 皮下注射劑

Participate Sites
5Sites

Recruiting5Sites

2024-07-15 - 2026-08-31

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2024-07-31 - 2031-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2024-08-01 - 2028-03-31

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2026-03-16 - 2031-11-30

Phase II

Not yet recruiting
A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER

  • Condition/Disease

    Small Cell Lung Cancer

  • Test Drug

    注射劑 注射劑 注射劑

Participate Sites
4Sites

Recruiting4Sites

2024-09-01 - 2032-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2024-09-01 - 2028-03-01

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

2026-04-01 - 2037-12-31

Phase III

Not yet recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)

  • Condition/Disease

    Leukemia, Lymphocytic, Chronic, B-Cell

  • Test Drug

    錠劑

Participate Sites
4Sites

Recruiting4Sites

2026-04-24 - 2029-07-31

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

  • Condition/Disease

    Pulmonary Arterial Hypertension

  • Test Drug

    吸入用膠囊劑

Participate Sites
3Sites

Recruiting3Sites

2026-05-01 - 2030-12-31

Phase III

Not yet recruiting
A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas

  • Condition/Disease

    Extrapulmonary Neuroendocrine Cancer (epNEC)

  • Test Drug

    注射用凍晶粉末 注射用懸液劑 注射用懸液劑

Participate Sites
3Sites

Recruiting2Sites

1 16 17 18 19 20 77
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB